This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.
This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Subjects will take study medication once daily for the duration of the study
Providence Care Hospital
Kingston, Ontario, Canada
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders
Time frame: Week 10
Generalized Anxiety Disorder - 7 (GAD-7)
The GAD-7 is a seven domain, self-reported questionnaire for screening and assessing severity of generalized anxiety disorder.
Time frame: Week 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.